Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.1209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Junkyu Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carbazoles, Anaplastic Lymphoma Kinase, Lung Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE: Alectinib has been approved for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at 300 mg twice daily in Japan, lower than global standard of 600 mg twice daily. This study evaluated the clinical relevance of the reduced dose by comparing outcomes between the two doses. MATERIALS AND METHODS: This study included patients with advanced ALK-positive NSCLC who received alectinib at Samsung Medical Center, Korea. The progression-free survival (PFS), overall survival, cumulative incidence of central nervous system (CNS) progression, and safety profiles were retrospectively reviewed and compared. RESULTS: Among 306 patients, 32 and 274 received alectinib at either 300 or 600 mg twice daily, respectively. The 300 mg group showed a slight but not significant advantage in PFS (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.44 to 1.51; p=0.51) and overall survival (HR, 0.51; 95% CI, 0.20 to 1.21; p=0.13). Superior outcome with 300 mg was remarkable in patients with lower body weight (≤ 60 kg), but diminished in patients with higher body weights. Patients with baseline brain metastasis in the 300 mg group exhibited a slight increase in incidence of CNS failure (HR, 1.76; 95% CI, 0.53 to 5.8; p=0.36). Although the safety profiles were mostly mild, adverse events were more frequent in the 600 mg group, 50% of which requiring dose reduction. CONCLUSION: Alectinib at 300 mg twice daily seems an acceptable dose in East Asians with ALK-positive NSCLC. Notably, our data favor 300 mg twice daily in patients with lower body weight and no baseline brain metastasis, considering the more tolerable safety profiles and the potential to reduce medical costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.
Zitieren
APA
Kim, J., Kim, M. J., Kim, J., Park, S., Jung, H. A., Lee, S. H., Ahn, J. S., Ahn, M. J., & Sun, J. M. (2025). Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.1209
Vancouver
Kim J, Kim MJ, Kim J, Park S, Jung HA, Lee SH, et al. Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.1209
BibTeX
@article{Kim2025,
author = {Kim, Junkyu and Kim, Min-Ji and Kim, Jinyong and Park, Sehhoon and Jung, Hyun Ae and Lee, Se-Hoon and Ahn, Jin Seok and Ahn, Myung-Ju and Sun, Jong-Mu},
title = {Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.1209}
}
EUVIMED